Literature DB >> 29871899

Myotonic dystrophy type 1: clinical manifestations in children and adolescents.

Genevieve Ho1, Kate A Carey1, Michael Cardamone1,2, Michelle A Farrar1,2.   

Abstract

OBJECTIVE: Myotonic dystrophy type 1 (DM1) is an autosomal-dominant neuromuscular disease with variable severity affecting all ages; however, current care guidelines are adult-focused. The objective of the present study was to profile DM1 in childhood and propose a framework to guide paediatric-focused management. DESIGN, SETTING AND PATIENTS: 40 children with DM1 (mean age 12.8 years; range 2-19) were studied retrospectively for a total of 513 follow-up years at Sydney Children's Hospital. 143 clinical parameters were recorded.
RESULTS: The clinical spectrum of disease in childhood differs from adults, with congenital myotonic dystrophy (CDM1) having more severe health issues than childhood-onset/juvenile patients (JDM1). Substantial difficulties with intellectual (CDM1 25/26 96.2%; JDM1 9/10, 90.0%), fine motor (CDM1 23/30, 76.6%; JDM1 6/10, 60.0%), gastrointestinal (CDM1 17/30, 70.0%; JDM1 3/10, 30.0%) and neuromuscular function (CDM1 30/30, 100.0%; JDM1 25/30, 83.3%) were evident.
CONCLUSION: The health consequences of DM1 in childhood are diverse, highlighting the need for paediatric multidisciplinary management approaches that encompass key areas of cognition, musculoskeletal, gastrointestinal, respiratory, cardiac and sleep issues. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  childhood myotonic dystrophy; clinical management; clinical manifestations; neuromuscular; quality of life

Mesh:

Year:  2018        PMID: 29871899     DOI: 10.1136/archdischild-2018-314837

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  7 in total

1.  12-Month progression of motor and functional outcomes in congenital myotonic dystrophy.

Authors:  Kellen H Quigg; Kiera N Berggren; Melissa McIntyre; Kameron Bates; Francesca Salmin; Jacopo L Casiraghi; Adele DʼAmico; Guja Astrea; Federica Ricci; Marnee J McKay; Jennifer N Baldwin; Joshua Burns; Craig Campbell; Valeria A Sansone; Nicholas E Johnson
Journal:  Muscle Nerve       Date:  2021-01-10       Impact factor: 3.217

2.  An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation.

Authors:  Emma Koehorst; Renato Odria; Júlia Capó; Judit Núñez-Manchón; Andrea Arbex; Miriam Almendrote; Ian Linares-Pardo; Daniel Natera-de Benito; Verónica Saez; Andrés Nascimento; Carlos Ortez; Miguel Ángel Rubio; Jordi Díaz-Manera; Jorge Alonso-Pérez; Giuseppe Lucente; Agustín Rodriguez-Palmero; Alba Ramos-Fransi; Alicia Martínez-Piñeiro; Gisela Nogales-Gadea; Mònica Suelves
Journal:  Biomedicines       Date:  2022-06-10

3.  Cardiac Manifestations of Myotonic Dystrophy in a Pediatric Cohort.

Authors:  Laia Brunet Garcia; Ankita Hajra; Ella Field; Joseph Wacher; Helen Walsh; Gabrielle Norrish; Adnan Manzur; Francesco Muntoni; Pinki Munot; Stephanie Robb; Rosaline Quinlivan; Mariacristina Scoto; Giovanni Baranello; Anna Sarkozy; Luke Starling; Juan Pablo Kaski; Elena Cervi
Journal:  Front Pediatr       Date:  2022-06-09       Impact factor: 3.569

Review 4.  Gastrointestinal motility disorders in neurologic disease.

Authors:  Michael Camilleri
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

5.  High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study.

Authors:  Alessia Perna; Daria Maccora; Salvatore Rossi; Tommaso Filippo Nicoletti; Maria Assunta Zocco; Vittorio Riso; Anna Modoni; Antonio Petrucci; Venanzio Valenza; Antonio Grieco; Luca Miele; Gabriella Silvestri
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

Review 6.  Myocardial and Arrhythmic Spectrum of Neuromuscular Disorders in Children.

Authors:  Anwar Baban; Valentina Lodato; Giovanni Parlapiano; Corrado di Mambro; Rachele Adorisio; Enrico Silvio Bertini; Carlo Dionisi-Vici; Fabrizio Drago; Diego Martinelli
Journal:  Biomolecules       Date:  2021-10-25

7.  Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in Motor Function or Insight.

Authors:  Mark J Hamilton; John McLean; Sarah Cumming; Bob Ballantyne; Josephine McGhie; Ravi Jampana; Cheryl Longman; Jonathan J Evans; Darren G Monckton; Maria Elena Farrugia
Journal:  Front Neurol       Date:  2018-10-02       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.